5 Mar 2024 • Recent study findings published in the journal JAMA suggest potential benefits for anemia incidence after SGLT2 inhibitor initiation in patients with T2D and CKD.

• Initiating sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) & chronic kidney disease (CKD) stages 1 to 3 may lead to a 19% reduction in incident anemia risk compared to glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
• A lower incidence of composite anemia outcomes, particularly anemia events, was observed among those on SGLT2 inhibitors.
• Changes in hemoglobin, hematocrit, and red blood cell counts during the follow-up period supported this observation.

Source: JAMA | Read full story